Jonathan Esensten, MD, PhD

Title(s)Assistant Professor, Laboratory Medicine
SchoolSchool of Medicine
Address513 Parnassus Ave, HSE
San Francisco CA 94143
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoM.D.2012 Medicine
    University of California, San FranciscoPh.D.2010 Graduate Division (Biomedical Sciences)
    University of California, San FranciscoResidency, Clinical Pathology2016Laboratory Medicine
    University of California, San FranciscoFellowship, Transfusion Medicine and Blood Banking2015Laboratory Medicine
    Collapse Awards and Honors
    University of California, San Francisco2016  - 2019Leukemia and Lymphoma Society Fellow
    San Francisco General Hospital2013  - 2013Krevans Award in Laboratory Medicine
    University of California, San Francisco2010  - 2010Alpha Omega Alpha Honor Society

    Collapse Overview 
    Collapse Overview
    Dr. Jonathan Esensten leads an experimental cellular therapy process development and manufacturing group. His group focusses on improving techniques for manufacturing T cell based therapies for patients with autoimmune disease, solid organ transplant, and cancer. He was a Leukemia and Lymphoma Society Fellow in the laboratory of Dr. Wendell Lim. He is co-director of the clinical Regulatory T Cell Manufacturing Group. He is also Medical Director of the UCSF HICTF and GMP Facility. He completed residency in clinical pathology and fellowship in transfusion medicine and blood banking at UCSF.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. Clin Infect Dis. 2020 Jul 14. Lynch KL, Whitman JD, Lacanienta NP, Beckerdite EW, Kastner SA, Shy BR, Goldgof GM, Levine AG, Bapat SP, Stramer SL, Esensten JH, Hightower AW, Bern C, Wu AHB. PMID: 32663256.
      View in: PubMed   Mentions: 1     Fields:    
    2. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. medRxiv. 2020 Jun 9; 2020.06.03.20121525. Kara Lake Lynch, Jeffrey D. Whitman, Noreen P Lacanienta, Erica W Beckerdite, Shannon A Kastner, Brian R Shy, Gregory M Goldgof, Andrew G Levine, Sagar P Bapat, Susan L Stramer, Jonathan H Esensten, Allen W Hightower, Caryn Bern, Alan HB Wu. .
      View in: Publisher Site   Mentions:
    3. 253-LB: Effect of Combined Low Dose IL-2 plus Polyclonal Tregs in Type 1 Diabetes Patients. Diabetes. 2019 Jun 1; 68(Supplement 1):253-lb. SHEN DONG, CODY T. MOWERY, KEVAN C. HEROLD, STEPHEN E. GITELMAN, JONATHAN H. ESENSTEN, WEIHONG LIU, ANGELA P. LARES, ASHLEY S. LEINBACH, MICHAEL R. LEE, VINH Q. NGUYEN, AMY L. PUTNAM, JIMMIE YE, QIZHI TANG, JEFFREY BLUESTONE. .
      View in: Publisher Site   Mentions:
    4. Development of a large-scale H3.3K27M-specific TCR-transduced T cell manufacturing method for adoptive cell therapy in HLA-A2+ patients with diffuse midline glioma. Cytotherapy. 2019 May 1; 21(5):s36. K. Okada, A. Nguyen, P. Watchmaker, J. Xu, F. Ramsdell, J.H. Esensten, L.H. Butterfield, H. Okada. .
      View in: Publisher Site   Mentions:
    5. Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier. J Allergy Clin Immunol. 2018 12; 142(6):1710-1718. Esensten JH, Muller YD, Bluestone JA, Tang Q. PMID: 30367909.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    6. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. 2018 07; 559(7714):405-409. Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, Hiatt J, Saco J, Krystofinski P, Li H, Tobin V, Nguyen DN, Lee MR, Putnam AL, Ferris AL, Chen JW, Schickel JN, Pellerin L, Carmody D, Alkorta-Aranburu G, Del Gaudio D, Matsumoto H, Morell M, Mao Y, Cho M, Quadros RM, Gurumurthy CB, Smith B, Haugwitz M, Hughes SH, Weissman JS, Schumann K, Esensten JH, May AP, Ashworth A, Kupfer GM, Greeley SAW, Bacchetta R, Meffre E, Roncarolo MG, Romberg N, Herold KC, Ribas A, Leonetti MD, Marson A. PMID: 29995861.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    7. 319 Developing a database to track critical parameters for clinical regulatory T cell manufacturing. Cytotherapy. 2018 May 1; 20(5):s108. B.R. Shy, J. Whitman, A.L. Putnam, A. Lares, Q. Tang, J.H. Esensten. .
      View in: Publisher Site   Mentions:
    8. 66 Low levels of EBV detected by PCR during manufacturing of clinical-grade stimulated B cells despite treatment with antiviral drugs. Cytotherapy. 2017 May 1; 19(5):s35. K. Lee, Q. Tang, J.H. Esensten. .
      View in: Publisher Site   Mentions:
    9. Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials. Annu Rev Pathol. 2017 Jan 24; 12:305-330. Esensten JH, Bluestone JA, Lim WA. PMID: 27959633.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    10. CD28 Costimulation: From Mechanism to Therapy. Immunity. 2016 05 17; 44(5):973-88. Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. PMID: 27192564.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansAnimalsCells
    11. Cdk8 deletion in the Apc(Min) murine tumour model represses EZH2 activity and accelerates tumourigenesis. J Pathol. 2015 Dec; 237(4):508-19. McCleland ML, Soukup TM, Liu SD, Esensten JH, de Sousa e Melo F, Yaylaoglu M, Warming S, Roose-Girma M, Firestein R. PMID: 26235356.
      View in: PubMed   Mentions: 11     Fields:    Translation:Animals
    12. Circulating proteolytic signatures of chemotherapy-induced cell death in humans discovered by N-terminal labeling. Proc Natl Acad Sci U S A. 2014 May 27; 111(21):7594-9. Wiita AP, Hsu GW, Lu CM, Esensten JH, Wells JA. PMID: 24821784.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    13. CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ T cell response. J Exp Med. 2013 Jul 29; 210(8):1603-19. Martínez-Llordella M, Esensten JH, Bailey-Bucktrout SL, Lipsky RH, Marini A, Chen J, Mughal M, Mattson MP, Taub DD, Bluestone JA. PMID: 23878307.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    14. microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis. J Immunol. 2013 Aug 15; 191(4):1594-605. de Kouchkovsky D, Esensten JH, Rosenthal WL, Morar MM, Bluestone JA, Jeker LT. PMID: 23858035.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansAnimalsCells
    15. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/?B7 family. Immunol Rev. 2011 May; 241(1):180-205. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. PMID: 21488898.
      View in: PubMed   Mentions: 134     Fields:    Translation:HumansAnimalsCells
    16. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol. 2011 Apr 01; 186(7):3918-26. McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, Hulme MA, Hoffmüller U, Baron U, Olek S, Bluestone JA, Brusko TM. PMID: 21368230.
      View in: PubMed   Mentions: 143     Fields:    Translation:HumansCells
    17. Plasticity of Human Regulatory T Cells - Characterization of IFN-?-Producing Cells. Clinical Immunology. 2010 Jan 1; 135:s5-s6. Stephanie McClymont, Amy Putnam, Michael Lee, Jonathan Esensten, Weihong Liu, Sven Olek, Udo Baron, Ulrich Hoffmuller, Jeffrey Bluestone, Todd Brusko. .
      View in: Publisher Site   Mentions:
    18. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol. 2009 Oct; 5(10):560-5. Esensten JH, Wofsy D, Bluestone JA. PMID: 19798031.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimalsCells
    19. T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J Immunol. 2009 Jul 01; 183(1):75-82. Esensten JH, Lee MR, Glimcher LH, Bluestone JA. PMID: 19535634.
      View in: PubMed   Mentions: 31     Fields:    Translation:AnimalsCells
    20. NFAT5 binds to the TNF promoter distinctly from NFATp, c, 3 and 4, and activates TNF transcription during hypertonic stress alone. Nucleic Acids Res. 2005; 33(12):3845-54. Esensten JH, Tsytsykova AV, Lopez-Rodriguez C, Ligeiro FA, Rao A, Goldfeld AE. PMID: 16027109.
      View in: PubMed   Mentions: 31     Fields:    Translation:AnimalsCells
    Jonathan's Networks
    Concepts (127)
    Derived automatically from this person's publications.
    Co-Authors (26)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department